Molina Healthcare is a Fortune 500 managed care organization focused almost exclusively on government-sponsored programs, primarily Medicaid and Medicare for low-income and dual-eligible members. This specialization gives MOH deep operational expertise in a segment where its Medicaid medical cost ratio (MCR — the share of premium revenue spent on medical care) has historically run roughly 300 to 400 basis points better than many peers, a meaningful structural advantage in a low-margin business.
Strategically, MOH is sharpening rather than diversifying. The company plans to exit its Medicare Advantage Prescription Drug (MAPD) line for 2027 and is deliberately reducing its Marketplace exposure after raising exchange pricing by roughly 30% in 2026. This concentrates the business on its most defensible franchises — Medicaid managed care and Medicare dual-eligible special needs plans — while management targets $64 billion in premium revenue and $25 in earnings per share (EPS) by 2029. Contract wins underscore this positioning: a historic Florida award, plus Georgia and Texas selections, add a visible multi-year revenue runway, even though the latter two face court-driven timing uncertainty. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The most consequential near-term catalyst is the state rate-setting cycle. MOH expects 2027 Medicaid rates near 6% against medical cost trend of 5.5% to 6%, the first year in which rates may broadly re-align with trend after a period of underfunding. Management has signaled that 2027 EPS "building blocks" already sum to more than $9.50 per share before any legacy margin improvement — a stark contrast to the roughly $5.25 guided for 2026.
Contract implementation timing is another swing factor. The Florida contract begins contributing in late 2026, while the Georgia and Texas awards have slipped to late 2027 or 2028 amid administrative and court reviews. Any clarity on those timelines would directly shape the revenue outlook. The planned MAPD exit and Marketplace downsizing should remove roughly $1.75 per share of combined losses from the 2027 base, simplifying the earnings path.
On analyst ratings, consensus remains a "Hold," with recent actions skewing cautious-to-neutral. Several firms — including Wells Fargo, Truist, and Morgan Stanley — have trimmed or maintained targets, while others such as Mizuho and Bernstein have reiterated more constructive views. Average price targets sit near $219 across roughly 19 analysts, with the range spanning from the low-to-mid $100s to above $260, reflecting genuine disagreement about how quickly Medicaid margins normalize.
MOH's trajectory is tightly linked to public-sector funding dynamics. State budget conditions, federal Medicaid matching rules, and policy debates over work requirements and eligibility redeterminations all influence both enrollment and rates. Rising medical cost trend — driven by specialty pharmaceuticals, behavioral health demand, and GLP-1 (glucagon-like peptide-1) obesity medications — is the central macro pressure point, since Medicaid rates typically reset with a lag.
Interest rates matter indirectly through MOH's capital structure and investment income, while inflation shapes both provider costs and the actuarial rate assumptions states adopt. A softer enrollment environment from work-requirement policies could trim membership in 2027, though MOH has noted many states are interpreting federal guidance in ways that lean toward retaining rather than disenrolling members. Overall, the industry is transitioning from a post-pandemic redetermination shock toward a more stable, rate-driven margin recovery phase — a shift that favors disciplined, low-cost operators like MOH.
The defining theme for 2026 is the compression and stabilization of Medicaid margins, followed by a projected recovery in 2027 as state rates incorporate elevated cost trend. MOH's guidance framework — roughly $42 billion in premium revenue and at least $5.25 in adjusted EPS for 2026, building toward more than $9.50 per share in 2027 — frames a clear earnings inflection that the market is attempting to price.
Longer term, several structural themes deserve attention. Market expansion through the Florida, Georgia, and Texas contracts and a stated $50 billion pipeline of new opportunities offers a growth runway independent of industry pricing. Cost structure and margin sustainability will hinge on MCR discipline and general and administrative (G&A) leverage, areas where MOH has historically outperformed. Regulatory developments — including Medicare Advantage rate notices, Medicaid work requirements, and program-integrity initiatives — remain the largest external variables. Capital allocation is also worth watching: with embedded earnings of roughly $9 per share and improving cash flow, share repurchases or deleveraging could supplement organic growth. Consensus expectations currently embed a cautious recovery, meaning any faster rate normalization or contract clarity could shift sentiment meaningfully.
In my analysis of MOH, I turned to Tickeron’s Trend Prediction Engine to get a data-driven view on potential short-term movements. This AI-powered tool helps assess whether a stock may trend bullish, bearish, or sideways over the coming weeks or months by drawing on historical patterns and searchable forecasts. It adds a useful quantitative layer alongside the fundamental outlook on rate recovery and contract ramps.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for MOH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 52 cases where MOH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on MOH as a result. In 57 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
MOH moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in 215 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 148 of 222 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
The 10-day RSI Indicator for MOH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Moving Average Convergence Divergence Histogram (MACD) for MOH turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 32 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
MOH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. MOH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.616) is normal, around the industry mean (3.520). MOH's P/E Ratio (1306.188) is considerably higher than the industry average of (126.353). Projected Growth (PEG Ratio) (0.880) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.233) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of health care services to persons eligible for Medicaid
Industry ManagedHealthCare